|
Activity Description
Treatment of metastatic breast cancer (MBC) remains a significant challenge. Novel therapies are needed to overcome resistance to current standard therapy with anthracyclines or taxanes, a situation compounded by the increasing use of the latter agents in the adjuvant setting. Understanding how novel therapies can best be incorporated into the treatment paradigm for MBC may be a significant challenge for the practicing oncologist. This educational activity will review key molecular pathways in breast tumor growth and the mechanism of action of microtubule-stabilizing agents, and will provide practical information on how novel microtubule-stabilizing agents can be integrated into the treatment of patients with MBC to improve outcomes.
Moderator
Harold J. Burstein, MD, PhD
Assistant Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts
Presenters
Marc L. Citron,, MD
Clinical Professor of Medicine
Albert Einstein College of Medicine
Yeshiva University
Bronx, New York
Linda T. Vahdat, MD
Associate Professor of Clinical Medicine
Weill Cornell Medical College
NewYork-Presbyterian Hospital
New York, New York
Learning Objectives
At the end of this educational activity, participants should be able to:
1. Identify new developments and research findings in the targeted treatment of metastatic breast cancer (MBC)
2. Describe recent clinical data on the treatment of patients with taxane-resistant and/or pretreated MBC
3. Assess preclinical data such as microtubule stability to facilitate clinical decisions and informed discussions with patients
Intended Audience
This CME activity is designed for physicians, nurses, pharmacists, and other health care professionals involved in the care of patients with metastatic breast cancer.
Accreditation Statements/Credit Designation:
OptumHealth Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
OptumHealth Education designates this educational activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
 The University of Florida College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is approved for 1 contact hour (0.1 CEU) in states that recognize ACPE.
To receive live credit, you must attend the entire session and complete the evaluation form. Statements of CE Credit will be issued by the University of Florida College of Pharmacy through OptumHealth Education upon successful completion of the activity. (Live–012-999-07-241-L01-P)
To receive enduring credit, you must pass the post-test with a score of at least 70% and complete the evaluation form. Statements of CE Credit will be issued by the University of Florida College of Pharmacy upon proof of successful completion of the activity. (Enduring–012-999-07-241-H01-P)
OptumHealth Education is an approved provider of continuing nursing education by the Utah Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. The participant will be awarded 1 contact hour of credit for attendance and completion of supplemental materials.
This activity is cosponsored by OptumHealth Education and the University of Florida College of Pharmacy.
Commercial Support:
This activity is supported by an unrestricted educational grant to OptumHealth Education from Bristol-Myers Squibb Company. |
|
*Registration required to receive
program materials.
|